summary of the product characteristics
... The clinical effects of tolterodine on QT interval were studied in ECGs obtained from over 600 treated patients, including the elderly and patients with pre-existing cardiovascular disease. The changes in QT intervals did not significantly differ between placebo and treatment groups. The effect of t ...
... The clinical effects of tolterodine on QT interval were studied in ECGs obtained from over 600 treated patients, including the elderly and patients with pre-existing cardiovascular disease. The changes in QT intervals did not significantly differ between placebo and treatment groups. The effect of t ...
here - The Therapeutics Initiative
... Mechanism of action: As with all antidepressants the mechanism of therapeutic benefit is unknown. It is an inhibitor of a number of receptors including adrenergic, serotonergic, histaminic and muscarinic. It is classified as an atypical antidepressant and is unrelated to tricyclics, selective seroto ...
... Mechanism of action: As with all antidepressants the mechanism of therapeutic benefit is unknown. It is an inhibitor of a number of receptors including adrenergic, serotonergic, histaminic and muscarinic. It is classified as an atypical antidepressant and is unrelated to tricyclics, selective seroto ...
Clinical Trials and Scientific Methods Chapter 0 Enrichment
... evaluate safety, side effects, and a safe dosage range. If Phase I is successful, Phase II will test an expanded group up to 100 people. Phase III studies more than 200 people to further determine safety, effectiveness, and side effects, and also to compare the drug to existing therapies. Phase IV s ...
... evaluate safety, side effects, and a safe dosage range. If Phase I is successful, Phase II will test an expanded group up to 100 people. Phase III studies more than 200 people to further determine safety, effectiveness, and side effects, and also to compare the drug to existing therapies. Phase IV s ...
Febuxostat - ACI Limited
... serum uric acid (SUA) less than 6 mg per dL after 2 weeks with 40 mg, Febuxostat 80 mg is recommended. Febuxostat can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Febuxostat to patients with mild to moderate renal or hepatic impairment. Us ...
... serum uric acid (SUA) less than 6 mg per dL after 2 weeks with 40 mg, Febuxostat 80 mg is recommended. Febuxostat can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Febuxostat to patients with mild to moderate renal or hepatic impairment. Us ...
Perampanel (Fycompa®) Clinicians initiating this medication should
... intolerable adverse events could remain on the same dose or have their dose decreased to the previously tolerated dose. In all three trials, the Titration Phase was followed by a Maintenance Phase that lasted 13 weeks, during which patients were to remain on a stable dose of Perampanel. The pooled 5 ...
... intolerable adverse events could remain on the same dose or have their dose decreased to the previously tolerated dose. In all three trials, the Titration Phase was followed by a Maintenance Phase that lasted 13 weeks, during which patients were to remain on a stable dose of Perampanel. The pooled 5 ...
Nimulid MD™ 100mg
... Nimulid MD ™ is a flavoured dispersible Nimesulide tablet with fast mouth dissolving characteristics thereby providing immediate relief. Nimesulide is a non-steroidal antiinflammatory drug (NSAID) indicated for the management of a variety of painful and inflammatory conditions like post operative pa ...
... Nimulid MD ™ is a flavoured dispersible Nimesulide tablet with fast mouth dissolving characteristics thereby providing immediate relief. Nimesulide is a non-steroidal antiinflammatory drug (NSAID) indicated for the management of a variety of painful and inflammatory conditions like post operative pa ...
Flupentixol + Melitracen
... and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline. Overdosage: Symptoms: Incase of overdosage the symptoms of intoxications by melitracen, especially of anticholinergic nature, dominat ...
... and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline. Overdosage: Symptoms: Incase of overdosage the symptoms of intoxications by melitracen, especially of anticholinergic nature, dominat ...
The Carlat Psychiatry Report ROZEREM (ramelteon) Fact Sheet
... to 5 hours. Thus, the overall half life may well be greater than 5 to 6 hours, depending on the individual. Since there is significant inter-individual variation in speed of metabolism, the duration of action will be very difficult to predict in a given patient. • No active metabolites. Metabolized ...
... to 5 hours. Thus, the overall half life may well be greater than 5 to 6 hours, depending on the individual. Since there is significant inter-individual variation in speed of metabolism, the duration of action will be very difficult to predict in a given patient. • No active metabolites. Metabolized ...
The pharmacology of type I hypersensitivity
... effects than antihistaminics. • They are beneficial in treatment of the symptoms of bronchial asthma,allargic rhinitis,and drug, serum, and transfusion allergic reactions.Yet, they are not curative . • Mechanism of action as anti-allergic drugs: they interfere in mast cell degranulation(i.e.mast cel ...
... effects than antihistaminics. • They are beneficial in treatment of the symptoms of bronchial asthma,allargic rhinitis,and drug, serum, and transfusion allergic reactions.Yet, they are not curative . • Mechanism of action as anti-allergic drugs: they interfere in mast cell degranulation(i.e.mast cel ...
Stilizan ®
... However, the probability of occurrence of extrapyramidal symptoms may be increased in some patients. Higher Doses: In physically healthy adults, the initials dose is 5 mg two times a day. Dosage can be increased up to 15 mg after one week. If more elevated doses are required, it should be administra ...
... However, the probability of occurrence of extrapyramidal symptoms may be increased in some patients. Higher Doses: In physically healthy adults, the initials dose is 5 mg two times a day. Dosage can be increased up to 15 mg after one week. If more elevated doses are required, it should be administra ...
famotidine (fa-moe-ti-deen) - DavisPlus
... Inform patient that smoking interferes with the action of histamine antagonists. Encourage patient to quit smoking or at least not to smoke after last dose of the day. May cause drowsiness or dizziness. Caution patient to avoid driving or other activities requiring alertness until response to the dr ...
... Inform patient that smoking interferes with the action of histamine antagonists. Encourage patient to quit smoking or at least not to smoke after last dose of the day. May cause drowsiness or dizziness. Caution patient to avoid driving or other activities requiring alertness until response to the dr ...
Antihistamines
... in humans have been encouraging, but the drug does have many potential side-effects—some serious—which is why the AUA guidelines list them as a last line of treatment for IC. Work with a healthcare professional experienced with immunosupressants if you a considering this ...
... in humans have been encouraging, but the drug does have many potential side-effects—some serious—which is why the AUA guidelines list them as a last line of treatment for IC. Work with a healthcare professional experienced with immunosupressants if you a considering this ...
Aller-Chlor - DavisPlus
... PO (Adults): 4 mg q 4– 6 hr or 8– 12 mg of extended-release formulation q 8– 12 hr (not to exceed 24 mg/day). PO (Geriatric Patients): 4 mg twice daily or 8 mg of extended-release formulation at bedtime. PO (Children 6– 12 yr): 2 mg 3– 4 times daily (not to exceed 12 mg/day). Subcut, IM, IV (Adults) ...
... PO (Adults): 4 mg q 4– 6 hr or 8– 12 mg of extended-release formulation q 8– 12 hr (not to exceed 24 mg/day). PO (Geriatric Patients): 4 mg twice daily or 8 mg of extended-release formulation at bedtime. PO (Children 6– 12 yr): 2 mg 3– 4 times daily (not to exceed 12 mg/day). Subcut, IM, IV (Adults) ...
Drugs Used to Treat Chronic Obstructive Pulmonary Disease
... allergic rhinitis.. Ocular and nasal antihistamine delivery devices are available over-the-counter for more targeted tissue delivery. Combinations of antihistamines with decongestants are effective when congestion is a feature of rhinitis.. α-Adrenergic agonists Short-acting α -adrenergic agonists ( ...
... allergic rhinitis.. Ocular and nasal antihistamine delivery devices are available over-the-counter for more targeted tissue delivery. Combinations of antihistamines with decongestants are effective when congestion is a feature of rhinitis.. α-Adrenergic agonists Short-acting α -adrenergic agonists ( ...
Prescribing Tip No.45 Date: 26th September 2014 Conditions for
... have a normal heart rhythm. It is also used in patients with long term heart failure who have a normal heart rhythm but whose heart rate is at least 75 beats per minute (bpm). ...
... have a normal heart rhythm. It is also used in patients with long term heart failure who have a normal heart rhythm but whose heart rate is at least 75 beats per minute (bpm). ...
L-Viava 1 g/10 ml 10 Vials of 10 ml
... L-Viava could be administered directly or dissolved in water or fruit juice. The drug should be administered at regular intervals 2-4 times a day, without regard to timing of food ingestion. To adults and children over 12 years it is prescribed in the doses of 2-6 g a day. The recommended dose of L- ...
... L-Viava could be administered directly or dissolved in water or fruit juice. The drug should be administered at regular intervals 2-4 times a day, without regard to timing of food ingestion. To adults and children over 12 years it is prescribed in the doses of 2-6 g a day. The recommended dose of L- ...
Clinical Trials PHASE 1
... To determine the dosage level of the drug. To evaluate how a new drug should be administered. Side effects of the drug. ...
... To determine the dosage level of the drug. To evaluate how a new drug should be administered. Side effects of the drug. ...
2016 department of medicine research day
... need. Lapatinib (L) plus capecitabine (C) yields a 20% objective response rate (ORR) in the CNS patients with previously treated HER2+ breast cancer brain metastases (Lin N, Clin Cancer Res 2009). Everolimus (E), an oral inhibitor of the mammalian target of rapamycin (mTOR), penetrates into the CNS ...
... need. Lapatinib (L) plus capecitabine (C) yields a 20% objective response rate (ORR) in the CNS patients with previously treated HER2+ breast cancer brain metastases (Lin N, Clin Cancer Res 2009). Everolimus (E), an oral inhibitor of the mammalian target of rapamycin (mTOR), penetrates into the CNS ...
March 2007 B BP PH
... oral or parenteral therapy. The most common adverse effects (occuring in less than 2% of patients in clinical trials) included paradoxical bronchospasm. Symptoms are described as chest discomfort, chest pain, asthma, bronchospasm, cough, dyspnea, obstructive airways disorder and wheezing. Hoarseness ...
... oral or parenteral therapy. The most common adverse effects (occuring in less than 2% of patients in clinical trials) included paradoxical bronchospasm. Symptoms are described as chest discomfort, chest pain, asthma, bronchospasm, cough, dyspnea, obstructive airways disorder and wheezing. Hoarseness ...
Press Release: FDA gives clearance to arimoclomol study for
... Interventional Study, European and US NP-C patients will receive oral arimoclomol or placebo three times daily for 12 months. All patients will subsequently be invited to join the open-label extension phase of the study, where everyone will receive arimoclomol. About Arimoclomol Arimoclomol is a sma ...
... Interventional Study, European and US NP-C patients will receive oral arimoclomol or placebo three times daily for 12 months. All patients will subsequently be invited to join the open-label extension phase of the study, where everyone will receive arimoclomol. About Arimoclomol Arimoclomol is a sma ...
Léčiva působící prostř. histaminu, serotoninu a dopaminu
... • Serotonine receptors: 5HT1A, 5-HT2, 5-HT3, 5-HT „xyz“ Clinical effects of activation/inhibition of serotonine receptors 5HT-1A agonist = anxiolytic and antidepressant eff. 5-HT2 antagonist eff. = antipsychotic eff., improvement of ...
... • Serotonine receptors: 5HT1A, 5-HT2, 5-HT3, 5-HT „xyz“ Clinical effects of activation/inhibition of serotonine receptors 5HT-1A agonist = anxiolytic and antidepressant eff. 5-HT2 antagonist eff. = antipsychotic eff., improvement of ...
Drug development
... • often patients where other treatment failed • OBJECTIVES: indication for use; type of patient; severity of disease; dose range, schedule and increment; pharmacokinetic studies in ill people; nature of side effects and severity; effects in special groups. ...
... • often patients where other treatment failed • OBJECTIVES: indication for use; type of patient; severity of disease; dose range, schedule and increment; pharmacokinetic studies in ill people; nature of side effects and severity; effects in special groups. ...
TAZAC®
... Hepatic--Hepatocellular injury, evidenced by elevated liver enzyme tests (SGOT [AST], SGPT [ALT], or alkaline phosphatase), occurred in some patients and was possibly or probably related to nizatidine. In some cases there was marked elevation of SGOT, SGPT enzymes (greater than 500 IU/L) and in a si ...
... Hepatic--Hepatocellular injury, evidenced by elevated liver enzyme tests (SGOT [AST], SGPT [ALT], or alkaline phosphatase), occurred in some patients and was possibly or probably related to nizatidine. In some cases there was marked elevation of SGOT, SGPT enzymes (greater than 500 IU/L) and in a si ...
secnidazole 500 mg Excipien
... - Adults: 1.5 g per day in one or more doses before meals, for 5 days. - Children: 30 mg/kg/day in one or more doses before meals, for 5 days. In the suppurative phase of hepatic amoebiasis, combine secnidazole treatment and removal of pus or lancing of abscesses Giardiasis: - Children: 30 mg/kg/day ...
... - Adults: 1.5 g per day in one or more doses before meals, for 5 days. - Children: 30 mg/kg/day in one or more doses before meals, for 5 days. In the suppurative phase of hepatic amoebiasis, combine secnidazole treatment and removal of pus or lancing of abscesses Giardiasis: - Children: 30 mg/kg/day ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.